<p>美国市场在过去一周保持平稳，但在过去 12 个月中上涨了 30%，预计年收益增长将达到 16%。在这种强劲的增长潜力背景下，识别高增长科技股需要关注那些展现出强大创新能力和适应能力的公司，以便抓住新兴机会。</p>
<h3>美国十大高增长科技公司</h3>
<table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>61.33%</td>
<td>65.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>27.35%</td>
<td>30.93%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Reddit</td>
<td>22.05%</td>
<td>27.75%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fabrinet</td>
<td>20.36%</td>
<td>22.11%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sandisk</td>
<td>34.05%</td>
<td>49.66%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Gorilla Technology Group</td>
<td>54.35%</td>
<td>95.02%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.95%</td>
<td>49.84%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>20.25%</td>
<td>46.50%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>36.60%</td>
<td>141.19%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>KVH Industries</td>
<td>25.44%</td>
<td>135.75%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们美国高增长科技和人工智能股票筛选器中的 67 只股票的完整列表。</p>
<p>让我们探索筛选结果中的几个突出选项。</p>
<h2>Gyre Therapeutics (GYRE)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Gyre Therapeutics, Inc.是一家制药公司，专注于开发和商业化用于治疗器官纤维化的小分子药物，市值为 6.7938 亿美元。</p>
<p><strong>运营：</strong> Gyre Therapeutics 专注于开发和商业化针对器官纤维化的小分子药物，主要通过其制药部门产生收入，该部门报告收入为 1.1659 亿美元。</p>
<p>尽管 Gyre Therapeutics 经历了一个充满挑战的年份，盈利下降 58.4%，但它仍然是生物技术领域创新的灯塔。该公司的收入增长预计为每年 20.5%，超过美国市场平均水平 11%，反映出强劲的基本商业动态。最近，Gyre 在监管进展方面取得了重大进展；其主要产品候选 Hydronidone 在中国获得了优先审查状态，用于治疗慢性乙型肝炎引起的肝纤维化，突显其对全球健康结果的潜在影响。此外，Gyre 与 Cullgen 的战略合并旨在增强其研究能力和市场覆盖，承诺在竞争压力和利润波动中实现强劲的未来增长前景。</p>
<ul>
<li>通过阅读我们的健康报告，深入了解 Gyre Therapeutics 的表现。</li>
<li>查看 Gyre Therapeutics 的过去表现报告，以了解其过去的表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/97ccc20e-42f8-49ae-93d0-40fda938d4d8/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/97ccc20e-42f8-49ae-93d0-40fda938d4d8/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2026 年 4 月的 GYRE 收入和支出明细</p>
<h2>Savara (SVRA)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Savara Inc.是一家临床阶段生物制药公司，致力于开发针对美国罕见呼吸疾病的治疗，市值为 13 亿美元。</p>
<p><strong>运营：</strong> Savara Inc.专注于开发针对美国罕见呼吸疾病的治疗，作为一家临床阶段生物制药公司，市值约为 13 亿美元。</p>
<p>Savara 在一系列监管活动中，正准备通过 MOLBREEVI 增强其市场地位，该药物目前正在接受 FDA 的优先审查，修订后的 PDUFA 日期定于 2026 年 11 月。此延期是 Savara 对 FDA 请求的全面回应的结果，强调了其在满足监管标准方面的承诺，没有任何安全或有效性方面的担忧。该公司的战略举措还包括在宾夕法尼亚州获得新的总部租约，并通过多场高端医学会议保持强劲的参与。这些步骤反映了 Savara 在应对复杂审批流程和扩大运营足迹方面的积极态度，这对于在竞争激烈的生物技术领域实现规模化至关重要。</p>
<ul>
<li>点击这里深入了解 Savara 的完整分析健康报告。</li>
<li>通过我们的过去报告获取 Savara 的历史趋势和表现的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/da6f666a-85e8-4cd7-a251-639ab8769d33/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/da6f666a-85e8-4cd7-a251-639ab8769d33/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2026 年 4 月的 SVRA 收入和支出明细</p>
<h2>Klaviyo (KVYO)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Klaviyo, Inc.提供基于云的软件即服务平台，覆盖包括美国、美国、亚太地区、英国、欧洲、中东和非洲在内的多个地区，市值约为 59.3 亿美元。</p>
<p><strong>运营：</strong> Klaviyo 运营一个基于云的 SaaS 平台，主要通过其互联网软件部门产生收入，该部门贡献了 12.3 亿美元。</p>
<p>Klaviyo 在追求创新的过程中，最近加深了与 Canva 和 Shopify 的整合，增强了营销人员设计和执行针对性活动的能力。这一合作至关重要，因为它利用了 Klaviyo 强大的数据分析能力，预计年收入增长为 16.2%，盈利预计将激增 81.7%。此外，该公司在研发方面的战略重点显而易见，进行了大量投资，旨在发展其营销自动化工具——这一举措不仅与行业向更灵活、数据驱动的营销解决方案的转变相一致，还显著提升了其在高风险科技领域的竞争优势。</p>
<ul>
<li>点击这里通过我们的综合健康报告深入了解 Klaviyo 的复杂性。</li>
<li>通过查看我们的过去表现报告获取 Klaviyo 的历史表现见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fb58748b-3872-42d2-b2b9-f2de2937c914/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fb58748b-3872-42d2-b2b9-f2de2937c914/chart/earnings-and-revenue-growth"/></p>
<p>KVYO 截至 2026 年 4 月的收益和收入增长</p>
<h2>利用机会</h2>
<ul>
<li>点击这里访问我们完整的 67 只美国高增长科技和人工智能股票指数。</li>
<li>投资了这些股票吗？通过 Simply Wall St 简化您的投资组合管理，并通过我们的警报及时了解您股票的任何重要更新。</li>
<li>通过 Simply Wall St 的免费应用程序发现投资机会的世界，并获取各市场无与伦比的股票分析。</li>
</ul>
<h2>对其他可能性感兴趣？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<h3><strong>新功能：</strong> 在一个地方管理您的所有股票投资组合</h3>
<p>我们为股票投资者创建了 <strong>终极投资组合助手</strong>，<strong>而且是免费的。</strong></p>
<p>• 连接无限数量的投资组合，并以一种货币查看您的总额</p>
<p>• 通过电子邮件或手机接收新的警告信号或风险提示</p>
<p>• 跟踪您股票的公允价值</p>
<p>免费试用演示投资组合</p>

KVYO

SVRA

GYRE

<p>美国市场在过去一年中上涨了 30%，预计年收益将增长 16%。关键的高增长科技股包括 Gyre Therapeutics、Savara 和 Klaviyo，这些公司均展现出强劲的收入和盈利增长。Gyre 专注于器官纤维化治疗，Savara 专注于罕见呼吸疾病，而 Klaviyo 提供基于云的 SaaS 平台。这些公司在竞争激烈的市场环境中具备强劲的增长潜力，显著的创新和战略举措增强了它们的市场存在感</p>

<p>The United States market remained flat over the last week, yet it has experienced a 30% rise over the past 12 months with earnings forecasted to grow by 16% annually. In this context of robust growth potential, identifying high-growth tech stocks involves focusing on companies that demonstrate strong innovation and adaptability to capitalize on emerging opportunities.</p>
<div class="lb-trans"><p>美国市场在过去一周保持平稳，但在过去 12 个月中上涨了 30%，预计年收益增长将达到 16%。在这种强劲的增长潜力背景下，识别高增长科技股需要关注那些展现出强大创新能力和适应能力的公司，以便抓住新兴机会。</p>
</div><h3>Top 10 High Growth Tech Companies In The United States</h3>
<div class="lb-trans"><h3>美国十大高增长科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>61.33%</td>
<td>65.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>27.35%</td>
<td>30.93%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Reddit</td>
<td>22.05%</td>
<td>27.75%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fabrinet</td>
<td>20.36%</td>
<td>22.11%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sandisk</td>
<td>34.05%</td>
<td>49.66%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Gorilla Technology Group</td>
<td>54.35%</td>
<td>95.02%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.95%</td>
<td>49.84%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>20.25%</td>
<td>46.50%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>36.60%</td>
<td>141.19%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>KVH Industries</td>
<td>25.44%</td>
<td>135.75%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>61.33%</td>
<td>65.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>27.35%</td>
<td>30.93%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Reddit</td>
<td>22.05%</td>
<td>27.75%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fabrinet</td>
<td>20.36%</td>
<td>22.11%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sandisk</td>
<td>34.05%</td>
<td>49.66%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Gorilla Technology Group</td>
<td>54.35%</td>
<td>95.02%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.95%</td>
<td>49.84%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>20.25%</td>
<td>46.50%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>36.60%</td>
<td>141.19%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>KVH Industries</td>
<td>25.44%</td>
<td>135.75%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 67 stocks from our US High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们美国高增长科技和人工智能股票筛选器中的 67 只股票的完整列表。</p>
</div><p>Let's explore several standout options from the results in the screener.</p>
<div class="lb-trans"><p>让我们探索筛选结果中的几个突出选项。</p>
</div><h2>Gyre Therapeutics (GYRE)</h2>
<div class="lb-trans"><h2>Gyre Therapeutics (GYRE)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Gyre Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing small-molecule drugs for treating organ fibrosis, with a market cap of $679.38 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Gyre Therapeutics, Inc.是一家制药公司，专注于开发和商业化用于治疗器官纤维化的小分子药物，市值为 6.7938 亿美元。</p>
</div><p><strong>Operations:</strong> Gyre Therapeutics focuses on developing and commercializing small-molecule drugs targeting organ fibrosis, generating revenue primarily from its pharmaceuticals segment, which reported $116.59 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> Gyre Therapeutics 专注于开发和商业化针对器官纤维化的小分子药物，主要通过其制药部门产生收入，该部门报告收入为 1.1659 亿美元。</p>
</div><p>Gyre Therapeutics, despite a challenging year with a 58.4% decline in earnings, remains a beacon of innovation within the biotech sector. The company's revenue growth forecast at 20.5% annually surpasses the US market average of 11%, reflecting strong underlying business dynamics. Recently, Gyre has made significant strides in regulatory advancements; its lead product candidate Hydronidone received priority review status in China for treating chronic hepatitis B-induced liver fibrosis, highlighting its potential impact on global health outcomes. Moreover, Gyre's strategic merger with Cullgen aims to enhance its research capabilities and market reach, promising robust future growth prospects amidst competitive pressures and fluctuating profit margins.</p>
<div class="lb-trans"><p>尽管 Gyre Therapeutics 经历了一个充满挑战的年份，盈利下降 58.4%，但它仍然是生物技术领域创新的灯塔。该公司的收入增长预计为每年 20.5%，超过美国市场平均水平 11%，反映出强劲的基本商业动态。最近，Gyre 在监管进展方面取得了重大进展；其主要产品候选 Hydronidone 在中国获得了优先审查状态，用于治疗慢性乙型肝炎引起的肝纤维化，突显其对全球健康结果的潜在影响。此外，Gyre 与 Cullgen 的战略合并旨在增强其研究能力和市场覆盖，承诺在竞争压力和利润波动中实现强劲的未来增长前景。</p>
</div><ul>
<li>Get an in-depth perspective on Gyre Therapeutics' performance by reading our health report here.</li>
<li>Examine Gyre Therapeutics' past performance report to understand how it has performed in the past.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过阅读我们的健康报告，深入了解 Gyre Therapeutics 的表现。</li>
<li>查看 Gyre Therapeutics 的过去表现报告，以了解其过去的表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/97ccc20e-42f8-49ae-93d0-40fda938d4d8/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/97ccc20e-42f8-49ae-93d0-40fda938d4d8/chart/revenue-and-expenses-breakdown"/></p>
<p>GYRE Revenue and Expenses Breakdown as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月的 GYRE 收入和支出明细</p>
</div><h2>Savara (SVRA)</h2>
<div class="lb-trans"><h2>Savara (SVRA)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Savara Inc. is a clinical-stage biopharmaceutical company dedicated to developing treatments for rare respiratory diseases in the United States, with a market cap of $1.30 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Savara Inc.是一家临床阶段生物制药公司，致力于开发针对美国罕见呼吸疾病的治疗，市值为 13 亿美元。</p>
</div><p><strong>Operations:</strong> Savara Inc. is focused on developing treatments for rare respiratory diseases in the U.S., operating as a clinical-stage biopharmaceutical company with a market cap of approximately $1.30 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> Savara Inc.专注于开发针对美国罕见呼吸疾病的治疗，作为一家临床阶段生物制药公司，市值约为 13 亿美元。</p>
</div><p>Savara, amidst a flurry of regulatory activities, is poised to enhance its market position with MOLBREEVI for autoimmune PAP, now under Priority Review by the FDA with a revised PDUFA date set for November 2026. This extension follows Savara's comprehensive response to the FDA's requests, underscoring its commitment to meeting regulatory standards without any noted concerns on safety or efficacy. The company’s strategic maneuvers also include securing a new headquarters lease in Pennsylvania and maintaining robust engagement through multiple high-profile medical conferences. These steps reflect Savara’s proactive approach in navigating complex approval processes and expanding its operational footprint, essential for scaling up in the competitive biotech landscape.</p>
<div class="lb-trans"><p>Savara 在一系列监管活动中，正准备通过 MOLBREEVI 增强其市场地位，该药物目前正在接受 FDA 的优先审查，修订后的 PDUFA 日期定于 2026 年 11 月。此延期是 Savara 对 FDA 请求的全面回应的结果，强调了其在满足监管标准方面的承诺，没有任何安全或有效性方面的担忧。该公司的战略举措还包括在宾夕法尼亚州获得新的总部租约，并通过多场高端医学会议保持强劲的参与。这些步骤反映了 Savara 在应对复杂审批流程和扩大运营足迹方面的积极态度，这对于在竞争激烈的生物技术领域实现规模化至关重要。</p>
</div><ul>
<li>Delve into the full analysis health report here for a deeper understanding of Savara.</li>
<li>Gain insights into Savara's past trends and performance with our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里深入了解 Savara 的完整分析健康报告。</li>
<li>通过我们的过去报告获取 Savara 的历史趋势和表现的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/da6f666a-85e8-4cd7-a251-639ab8769d33/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/da6f666a-85e8-4cd7-a251-639ab8769d33/chart/revenue-and-expenses-breakdown"/></p>
<p>SVRA Revenue and Expenses Breakdown as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月的 SVRA 收入和支出明细</p>
</div><h2>Klaviyo (KVYO)</h2>
<div class="lb-trans"><h2>Klaviyo (KVYO)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Klaviyo, Inc. offers a cloud-based software-as-a-service platform across various regions including the United States, the Americas, Asia-Pacific, the United Kingdom, Europe, the Middle East, and Africa with a market cap of approximately $5.93 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Klaviyo, Inc.提供基于云的软件即服务平台，覆盖包括美国、美国、亚太地区、英国、欧洲、中东和非洲在内的多个地区，市值约为 59.3 亿美元。</p>
</div><p><strong>Operations:</strong> Klaviyo operates a cloud-based SaaS platform, generating revenue primarily from its Internet Software segment, which contributed $1.23 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> Klaviyo 运营一个基于云的 SaaS 平台，主要通过其互联网软件部门产生收入，该部门贡献了 12.3 亿美元。</p>
</div><p>Klaviyo, in its pursuit of innovation, has recently deepened its integration with Canva and Shopify, enhancing marketers' ability to design and execute targeted campaigns efficiently. This collaboration is pivotal as it leverages Klaviyo's robust data analytics capabilities, evidenced by a 16.2% annual revenue growth forecast and an impressive expected earnings surge of 81.7% per year. Additionally, the company's strategic focus on R&amp;D is clear with substantial investments aimed at evolving their marketing automation tools—a move that not only aligns with industry shifts towards more agile, data-driven marketing solutions but also significantly boosts their competitive edge in the high-stakes tech landscape.</p>
<div class="lb-trans"><p>Klaviyo 在追求创新的过程中，最近加深了与 Canva 和 Shopify 的整合，增强了营销人员设计和执行针对性活动的能力。这一合作至关重要，因为它利用了 Klaviyo 强大的数据分析能力，预计年收入增长为 16.2%，盈利预计将激增 81.7%。此外，该公司在研发方面的战略重点显而易见，进行了大量投资，旨在发展其营销自动化工具——这一举措不仅与行业向更灵活、数据驱动的营销解决方案的转变相一致，还显著提升了其在高风险科技领域的竞争优势。</p>
</div><ul>
<li>Navigate through the intricacies of Klaviyo with our comprehensive health report here.</li>
<li>Gain insights into Klaviyo's historical performance by reviewing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里通过我们的综合健康报告深入了解 Klaviyo 的复杂性。</li>
<li>通过查看我们的过去表现报告获取 Klaviyo 的历史表现见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fb58748b-3872-42d2-b2b9-f2de2937c914/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/fb58748b-3872-42d2-b2b9-f2de2937c914/chart/earnings-and-revenue-growth"/></p>
<p>KVYO Earnings and Revenue Growth as at Apr 2026</p>
<div class="lb-trans"><p>KVYO 截至 2026 年 4 月的收益和收入增长</p>
</div><h2>Taking Advantage</h2>
<div class="lb-trans"><h2>利用机会</h2>
</div><ul>
<li>Click here to access our complete index of 67 US High Growth Tech and AI Stocks.</li>
<li>Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.</li>
<li>Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里访问我们完整的 67 只美国高增长科技和人工智能股票指数。</li>
<li>投资了这些股票吗？通过 Simply Wall St 简化您的投资组合管理，并通过我们的警报及时了解您股票的任何重要更新。</li>
<li>通过 Simply Wall St 的免费应用程序发现投资机会的世界，并获取各市场无与伦比的股票分析。</li>
</ul>
</div><h2>Interested In Other Possibilities?</h2>
<div class="lb-trans"><h2>对其他可能性感兴趣？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><h3><strong>New:</strong> Manage All Your Stock Portfolios in One Place</h3>
<div class="lb-trans"><h3><strong>新功能：</strong> 在一个地方管理您的所有股票投资组合</h3>
</div><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p>
<div class="lb-trans"><p>我们为股票投资者创建了 <strong>终极投资组合助手</strong>，<strong>而且是免费的。</strong></p>
</div><p>• Connect an unlimited number of Portfolios and see your total in one currency</p>
<div class="lb-trans"><p>• 连接无限数量的投资组合，并以一种货币查看您的总额</p>
</div><p>• Be alerted to new Warning Signs or Risks via email or mobile</p>
<div class="lb-trans"><p>• 通过电子邮件或手机接收新的警告信号或风险提示</p>
</div><p>• Track the Fair Value of your stocks</p>
<div class="lb-trans"><p>• 跟踪您股票的公允价值</p>
</div><p>Try a Demo Portfolio for Free</p>
<div class="lb-trans"><p>免费试用演示投资组合</p>
</div>

值得关注的美国高增长科技股